Shaping the future of precision medicine through data integration
The healthcare industry is undergoing a fundamental shift toward a data-driven era, where the integration of clinical, genomic, pathological, and imaging data is essential to advancing precision medicine.
As the first company in Korea to commercialize an NGS-based precision diagnostics platform, NGeneBio has built a strong foundation in genomic analysis and a deep understanding of hospital workflows. Building on this foundation, we are expanding our capabilities toward a multimodal, data-driven precision diagnostics platform to support more personalized and patient-specific care.
As the first company in Korea to commercialize an NGS-based precision diagnostics platform, NGeneBio has built a strong foundation in genomic analysis and a deep understanding of hospital workflows. Building on this foundation, we are expanding our capabilities toward a multimodal, data-driven precision diagnostics platform to support more personalized and patient-specific care.
By combining multimodal medical data with AI-based analytical technologies, we are strengthening the foundation for faster and more meaningful interpretation of complex medical information across both clinical practice and research.
Looking ahead, NGeneBio will continue to build on its NGS-based biotechnology and AI analytics capabilities, with a clear focus on translating medical data into practical value at the point of care. Through this journey, we aim to grow as an AI-driven precision medicine company that contributes to the creation of new and sustainable value in healthcare.
Thank you.
CEO Min-sik Kim